CA19-9 Antibody [C17A13]

Catalog No.: F2466

Application: Reactivity: Human

Immunohistochemical analysis of formalin fixed paraffin embedded human colorectal cancer tissue with F2466 at 1:100 dilution.

当該製品は品切れ状态で、ごメールアドレスを教えていただければ、在庫があると、メールで顧客様に伝えます。

代表番号: 045-509-1970|電子メール：sales@selleck.co.jp

使用情報

Dilution
IHC1:100

Application
IHC, FCM, ELISA

Source
Mouse Monoclonal Antibody

Reactivity
Human

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

ポジティブコントロール	Human colorectal adenocarcinoma
ネガティブコントロール

プロトコール

IHC
Experimental Protocol： Deparaffinization/Rehydration 1. Deparaffinize/hydrate sections: 2. Incubate sections in three washes of xylene for 5 min each. 3. Incubate sections in two washes of 100% ethanol for 10 min each. 4. Incubate sections in two washes of 95% ethanol for 10 min each. 5. Wash sections two times in dH2O for 5 min each. 6.Antigen retrieval: For Citrate: Heat slides in a microwave submersed in 1X citrate unmasking solution until boiling is initiated; continue with 10 min at a sub-boiling temperature (95°-98°C). Cool slides on bench top for 30 min. Staining 1. Wash sections in dH2O three times for 5 min each. 2. Incubate sections in 3% hydrogen peroxide for 10 min. 3. Wash sections in dH2O two times for 5 min each. 4. Wash sections in wash buffer for 5 min. 5. Block each section with 100–400 µl of blocking solution for 1 hr at room temperature. 6. Remove blocking solution and add 100–400 µl primary antibody diluent in to each section. Incubate overnight at 4°C. 7. Remove antibody solution and wash sections with wash buffer three times for 5 min each. 8. Cover section with 1–3 drops HRPas needed. Incubate in a humidified chamber for 30 min at room temperature. 9. Wash sections three times with wash buffer for 5 min each. 10. Add DAB Chromogen Concentrate to DAB Diluent and mix well before use. 11. Apply 100–400 µl DAB to each section and monitor closely. 1–10 min generally provides an acceptable staining intensity. 12. Immerse slides in dH2O. 13. If desired, counterstain sections with hematoxylin. 14. Wash sections in dH2O two times for 5 min each. 15. Dehydrate sections: Incubate sections in 95% ethanol two times for 10 sec each; Repeat in 100% ethanol, incubating sections two times for 10 sec each; Repeat in xylene, incubating sections two times for 10 sec each. 16. Mount sections with coverslips and mounting medium.

IHC

Experimental Protocol：

Deparaffinization/Rehydration

1. Deparaffinize/hydrate sections:

2. Incubate sections in three washes of xylene for 5 min each.

3. Incubate sections in two washes of 100% ethanol for 10 min each.

4. Incubate sections in two washes of 95% ethanol for 10 min each.

5. Wash sections two times in dH2O for 5 min each.

6.Antigen retrieval: For Citrate: Heat slides in a microwave submersed in 1X citrate unmasking solution until boiling is initiated; continue with 10 min at a sub-boiling temperature (95°-98°C). Cool slides on bench top for 30 min.

Staining

1. Wash sections in dH2O three times for 5 min each.

2. Incubate sections in 3% hydrogen peroxide for 10 min.

3. Wash sections in dH2O two times for 5 min each.

4. Wash sections in wash buffer for 5 min.

5. Block each section with 100–400 µl of blocking solution for 1 hr at room temperature.

6. Remove blocking solution and add 100–400 µl primary antibody diluent in to each section. Incubate overnight at 4°C.

7. Remove antibody solution and wash sections with wash buffer three times for 5 min each.

8. Cover section with 1–3 drops HRPas needed. Incubate in a humidified chamber for 30 min at room temperature.

9. Wash sections three times with wash buffer for 5 min each.

10. Add DAB Chromogen Concentrate to DAB Diluent and mix well before use.

11. Apply 100–400 µl DAB to each section and monitor closely. 1–10 min generally provides an acceptable staining intensity.

12. Immerse slides in dH2O.

13. If desired, counterstain sections with hematoxylin.

14. Wash sections in dH2O two times for 5 min each.

15. Dehydrate sections: Incubate sections in 95% ethanol two times for 10 sec each; Repeat in 100% ethanol, incubating sections two times for 10 sec each; Repeat in xylene, incubating sections two times for 10 sec each.

16. Mount sections with coverslips and mounting medium.

Datasheet & SDS

生物学的記述

Specificity
CA19-9 Antibody [C17A13] detects endogenous levels of CA 19-9 protein.

Clone
C17A13

Synonym(s)
CA19.9, Ovarian tumor antigen, Pancreatic tumor antigen, Sialyl Lewis a

Background
CA19-9 (Carbohydrate antigen 19-9), also known as Sialyl Lewis A (sLeᵃ), is a sialylated Lewis blood group antigen, a tetrasaccharide glycan epitope composed of sialic acid, galactose, N-acetylglucosamine, and fucose, biosynthesized via the Lewis blood group pathway and requiring a functional Lewis antigen for its formation. CA19-9 is expressed on glycoproteins and glycolipids of epithelial cell membranes, particularly in the pancreas, biliary tract, stomach, and colon, and can be shed into the bloodstream. It is the current gold-standard serum biomarker for pancreatic adenocarcinoma. Functionally, CA19-9 serves as a biomarker (for diagnosis, prognosis, monitoring treatment response, and detecting recurrence), a predictor (correlating with tumor burden, stage, and resectability), and a promoter of cancer progression by facilitating E-selectin–mediated adhesion, enhancing angiogenesis, modulating immune responses, and influencing tumor microenvironment interactions. Beyond pancreatic cancer, CA19-9 is elevated in other gastrointestinal malignancies and certain benign diseases, and is under investigation as a therapeutic target via antibodies, vaccines, biosynthesis inhibitors, and CA19-9–guided drug delivery systems.

Background

CA19-9 (Carbohydrate antigen 19-9), also known as Sialyl Lewis A (sLeᵃ), is a sialylated Lewis blood group antigen, a tetrasaccharide glycan epitope composed of sialic acid, galactose, N-acetylglucosamine, and fucose, biosynthesized via the Lewis blood group pathway and requiring a functional Lewis antigen for its formation. CA19-9 is expressed on glycoproteins and glycolipids of epithelial cell membranes, particularly in the pancreas, biliary tract, stomach, and colon, and can be shed into the bloodstream. It is the current gold-standard serum biomarker for pancreatic adenocarcinoma. Functionally, CA19-9 serves as a biomarker (for diagnosis, prognosis, monitoring treatment response, and detecting recurrence), a predictor (correlating with tumor burden, stage, and resectability), and a promoter of cancer progression by facilitating E-selectin–mediated adhesion, enhancing angiogenesis, modulating immune responses, and influencing tumor microenvironment interactions. Beyond pancreatic cancer, CA19-9 is elevated in other gastrointestinal malignancies and certain benign diseases, and is under investigation as a therapeutic target via antibodies, vaccines, biosynthesis inhibitors, and CA19-9–guided drug delivery systems.

References
[1] Luo G, et al. Biochim Biophys Acta Rev Cancer. 2021 Apr;1875(2):188409. [2] Farley AM, et al. Sci Rep. 2019 Feb 27;9(1):2876.

PVDFメンブレン孔径参考表

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

* 大学・企業名 大学・企業名を記入してください

* 名前 名前を記入してください

* 電子メール 電子メール・アドレスを記入してください 有効なメールアドレスを入力してください

電話番号

* 内容 お問い合わせ内容をご入力ください

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%